Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/135580
Title: THE USE OF FUSOGENIC LIPIDS AND HDAC6 INHIBITORS TO ENHANCE GENE DELIVERY
Authors: TAN BING QUAN JUSTIN
Keywords: HDAC inhibitor, Gene delivery, non-viral gene delivery, fusogenic lipids, lentivirus, mesenchymal stem cells
Issue Date: 13-Feb-2017
Citation: TAN BING QUAN JUSTIN (2017-02-13). THE USE OF FUSOGENIC LIPIDS AND HDAC6 INHIBITORS TO ENHANCE GENE DELIVERY. ScholarBank@NUS Repository.
Abstract: There are growing studies with evidence that ex vivo genetic modifications of human cells, improve therapeutic potentials. Conventional viral vectors are favourable, but hindered by large-scale production issues. Currently, lentivirus production relies on transient transfection which are poor and inconsistent. Previously, the barriers to transient transfection of hard-to-transfect cells was systematically identified and eventually mitigated with the use of DOPE/CHEMS and HDAC6 inhibitors in a cationic-polymer based transfection workflow. As an extension, multiple-plasmid transfection was shown to be similarly enhanced, translating to higher lentivirus production. DOPE/CHEMS and SAHA also significantly enhanced transduction of hard-to-transduce cells. Another emerging therapy is the delivery of therapeutic proteins with genetically-modified cellular vehicles like MSC, which are poorly and inconsistently transfected. In our UC-MSC model, DOPE/CHEMS and HDAC6 inhibitors enhanced MSC transfection, resulting in increased functional protein release. Overall, these studies provide novel findings and is translatable to a wide range of applications.
URI: http://scholarbank.nus.edu.sg/handle/10635/135580
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
TanBQJ.pdf5.82 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

76
checked on May 22, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.